Study on the Mechanism of Selective Interaction of BR3 and BCMA with BAFF and APRIL
- 16 November 2020
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Protein & Peptide Letters
- Vol. 27 (11) , 1114-1123
Abstract
Background: B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) can activate signaling pathways by binding to specific receptors. BR3 (BAFF receptor) shows a unique selectivity for BAFF ligand, while B-cell maturation antigen (BCMA) exhibits a stronger interaction between APRIL-BCMA rather than BAFF-BCMA interaction. Objective: The combined domains were fused with IgG1 Fc to better understand which domain affects the selective interaction of the receptor with BAFF and APRIL. Methods: Since BR3 and BCMA both contain cysteine-rich repeat domains (CRD) with DxL motif, the binding domains of BR3 and BCMA were segmented into two parts in this study. BR3-1 (CFDLLVRHGVAC) and BCMA-1 (YFDSLLHACIPC) contained the conservative DxL motif, while BR3-2 (GLLRTPRPKPA) and BCMA-2 (QLRCSSNTPPLT) were adjacent to the CRDs yet still joined with BR3-1 and BCMA-1. Affinity between all possible combinations was then tested. Results: The affinity of BR3-1-BCMA-2-Fc and BR3-1-BR3-2-Fc for BAFF was higher than BCMA-1-BR3-2-Fc and BCMA-1-BCMA-2-Fc. Moreover, BR3-1-BCMA-2-Fc and BCMA-1-BCMA- 2-Fc had affinity for APRIL, while BR3-1-BR3-2-Fc and BCMA-1-BR3-2-Fc hardly interacted with APRIL. Conclusion: BR3-1 region played a key role for interaction with BAFF, while BCMA-1 region exhibited weaker binding with BAFF. BCMA-2 region having an α-helix might contribute towards selectivity of APRIL-BCMA binding and BR3-2 rigid region had deleterious effects on the APRIL-BR3 interaction. These results provide comprehensive insights of the mechanism of selective interactions, and may promote specific antagonist design in the future.Keywords
Funding Information
- National Natural Science Foundation of China (81273308)
This publication has 75 references indexed in Scilit:
- Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trialsAnnals of the Rheumatic Diseases, 2012
- Selection of a Novel and Highly Specific Tumor Necrosis Factor α (TNFα) AntagonistJournal of Biological Chemistry, 2010
- BAFF-R promotes cell proliferation and survival through interaction with IKKβ and NF-κB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cellsBlood, 2009
- Structure–Function Relationship of Tumor Necrosis Factor (TNF) and Its Receptor Interaction Based on 3D Structural Analysis of a Fully Active TNFR1-Selective TNF MutantJournal of Molecular Biology, 2009
- Shared Principles in NF-κB SignalingCell, 2008
- BAFF and MyD88 signals promote a lupuslike disease independent of T cellsJournal of Experimental Medicine, 2007
- The Crystal Structure of A Proliferation-inducing Ligand, APRILJournal of Molecular Biology, 2004
- Multiple sequence alignment with the Clustal series of programsNucleic Acids Research, 2003
- Crystal structure of the BAFF–BAFF-R complex and its implications for receptor activationNature Structural & Molecular Biology, 2003
- Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytesJournal of Molecular Biology, 2002